{"id":1186,"date":"2016-09-06T17:26:42","date_gmt":"2016-09-06T11:56:42","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1186"},"modified":"2023-06-16T10:40:59","modified_gmt":"2023-06-16T05:10:59","slug":"the-snippet-astrazenecas-new-asthma-drug-aces-phase-iii-trial","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-snippet-astrazenecas-new-asthma-drug-aces-phase-iii-trial","title":{"rendered":"AstraZeneca\u2019s new Asthma Drug Aces Phase III trial"},"content":{"rendered":"<p style=\"text-align: justify;\">AstraZeneca has got good results in the clinical trial for its next-generation asthma medication and could be available to patients by the end of next year. The drug, Benralizumab, is a new biological treatment for people with severe asthma, and works by targeting eosinophils that cause inflammation in the lungs of some patients with severe, uncontrolled asthma.<\/p>\n<blockquote><p><em>Benralizumab is Astra\u2019s first biologic respiratory medication to pass Phase III trials, with the company hoping to file with US regulators before the end of this year. <\/em><\/p><\/blockquote>\n<p style=\"text-align: justify;\">However, Benralizumab does not have first-mover advantage as GlaxoSmithKline and Teva Pharmaceuticals already have two eosinophil-targeting asthma drugs on the market, Nucala and Cinquil, launched in the past year. Nevertheless, Nucala and Cinquil target the hormone that contributes to eosinophil production, whereas Benralizumab targets the actual white blood cell by binding to its receptor and blocking it.<\/p>\n<blockquote><p>AstraZeneca also has plans for further clinical trials with benralizumab, including one to see whether patients who take it can be weaned off oral steroids. The drug will also be tested in people with chronic obstructive pulmonary disease (COPD) over the next two years.<\/p><\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca has got good results in the clinical trial for its next-generation asthma medication and could be available to patients by the end of next year. The drug, Benralizumab, is a new biological treatment for people with severe asthma, and works by targeting eosinophils that cause inflammation in the lungs of some patients with severe, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1190,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[1875,96,17315,719,17316,718,985,1793,17314],"industry":[17225],"therapeutic_areas":[17237,17243],"class_list":["post-1186","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-asthma","tag-astrazeneca","tag-benralizumab","tag-chronic-obstructive-pulmonary-disease","tag-cinquil","tag-copd","tag-glaxosmithkline","tag-nucala","tag-teva-pharmaceuticals","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Asthma Drug | AstraZeneca&#039;s Benralizumab Aces Phase III trial<\/title>\n<meta name=\"description\" content=\"AstraZeneca has got good results in the clinical trial for its next-generation asthma medication and could be available to patients by the end of next year\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-astrazenecas-new-asthma-drug-aces-phase-iii-trial\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Asthma Drug | AstraZeneca&#039;s Benralizumab Aces Phase III trial\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca has got good results in the clinical trial for its next-generation asthma medication and could be available to patients by the end of next year\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-astrazenecas-new-asthma-drug-aces-phase-iii-trial\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-09-06T11:56:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-16T05:10:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/12062943\/lungs_istock.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2861\" \/>\n\t<meta property=\"og:image:height\" content=\"3000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Asthma Drug | AstraZeneca's Benralizumab Aces Phase III trial","description":"AstraZeneca has got good results in the clinical trial for its next-generation asthma medication and could be available to patients by the end of next year","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-snippet-astrazenecas-new-asthma-drug-aces-phase-iii-trial","og_locale":"en_US","og_type":"article","og_title":"Asthma Drug | AstraZeneca's Benralizumab Aces Phase III trial","og_description":"AstraZeneca has got good results in the clinical trial for its next-generation asthma medication and could be available to patients by the end of next year","og_url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-astrazenecas-new-asthma-drug-aces-phase-iii-trial","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-09-06T11:56:42+00:00","article_modified_time":"2023-06-16T05:10:59+00:00","og_image":[{"width":2861,"height":3000,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/12062943\/lungs_istock.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-astrazenecas-new-asthma-drug-aces-phase-iii-trial","url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-astrazenecas-new-asthma-drug-aces-phase-iii-trial","name":"Asthma Drug | AstraZeneca's Benralizumab Aces Phase III trial","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-astrazenecas-new-asthma-drug-aces-phase-iii-trial#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-astrazenecas-new-asthma-drug-aces-phase-iii-trial#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/12062943\/lungs_istock.jpg","datePublished":"2016-09-06T11:56:42+00:00","dateModified":"2023-06-16T05:10:59+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"AstraZeneca has got good results in the clinical trial for its next-generation asthma medication and could be available to patients by the end of next year","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-snippet-astrazenecas-new-asthma-drug-aces-phase-iii-trial"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-astrazenecas-new-asthma-drug-aces-phase-iii-trial#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/12062943\/lungs_istock.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/12062943\/lungs_istock.jpg","width":2861,"height":3000},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/12062943\/lungs_istock-286x300.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">asthma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Benralizumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cinquil<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">COPD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Nucala<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Teva Pharmaceuticals<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">asthma<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Benralizumab<\/span>","<span class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease<\/span>","<span class=\"advgb-post-tax-term\">Cinquil<\/span>","<span class=\"advgb-post-tax-term\">COPD<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">Nucala<\/span>","<span class=\"advgb-post-tax-term\">Teva Pharmaceuticals<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Sep 6, 2016","modified":"Updated on Jun 16, 2023"},"absolute_dates_time":{"created":"Posted on Sep 6, 2016 5:26 pm","modified":"Updated on Jun 16, 2023 10:40 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1186"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1186\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1190"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1186"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1186"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}